Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Acquisitions drive first-half revenue growth for Luceco

(Sharecast News) - Luceco reported a 15% increase in revenue for the first half of 2025 on Tuesday, reaching £125m, supported by recent acquisitions and continued growth in electric vehicle charging products. In a trading update, the London-listed electrical products manufacturer said adjusted operating profit rose by around 10% to between £13.5m and £13.8m, with margins at roughly 11%, reflecting typical seasonal effects.

It cited strong contributions from D-Line and CMD, both acquired in 2024, and noted significant progress in integrating CMD into its supply chain.

"We are well positioned for another year of encouraging growth and strategic progress, driven by the breadth of our product range, our established market position, flexible manufacturing capability and the successful integrations of the recent acquisitions of D-Line and CMD," said chief executive John Hornby.

He added that the group's "robust balance sheet, recent refinancing and good cash generation provide optionality to invest in the business both organically and through mergers and acquisitions to drive future growth."

The company said it maintained a bank net debt-to-EBITDA ratio of around 1.6x, within its target range, and recently secured a new £120m revolving credit facility.

Full-year expectations remained unchanged, with the board pointing to improving operational efficiency, limited exposure to US-China tariffs, and strong forward demand indicators as key supports for its outlook.

At 1047 BST, shares in Luceco were up 1.14% at 141.4p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.